Premium
Is there an association between neurocognitive performance and medication adherence in first episode psychosis?
Author(s) -
Lepage Martin,
Bodnar Michael,
Joober Ridha,
Malla Ashok
Publication year - 2010
Publication title -
early intervention in psychiatry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.087
H-Index - 45
eISSN - 1751-7893
pISSN - 1751-7885
DOI - 10.1111/j.1751-7893.2010.00174.x
Subject(s) - neurocognitive , psychosis , cognition , medication adherence , association (psychology) , psychiatry , schizophrenia (object oriented programming) , psychology , clinical psychology , medicine , psychotherapist
Aim: Medication adherence is a determining factor for symptomatic remission and relapse prevention following a first episode of psychosis (FEP). Neurocognitive abilities have received only scant attention so far as a risk factor for poor adherence but significant impairments with memory and/or planning abilities could play a role. We examined early medication adherence following admission to a specialized clinical programme for FEP. Method: One hundred sixty FEP participants and 35 healthy controls completed an exhaustive neurocognitive assessment. FEP participants were categorized as a function of their medication adherence at 6 months into poor ( n = 34), partial ( n = 27) and full ( n = 99) adherence, respectively. Domain‐specific and global measures of cognitive ability were examined. Results: No measure of neurocognition could significantly discriminate amongst the three medication adherence groups. Conclusion: These results suggest no strong associations between neurocognitive abilities and medication adherence in first episode of psychosis.